CO2023006516A2 - Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabry - Google Patents

Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabry

Info

Publication number
CO2023006516A2
CO2023006516A2 CONC2023/0006516A CO2023006516A CO2023006516A2 CO 2023006516 A2 CO2023006516 A2 CO 2023006516A2 CO 2023006516 A CO2023006516 A CO 2023006516A CO 2023006516 A2 CO2023006516 A2 CO 2023006516A2
Authority
CO
Colombia
Prior art keywords
prevention
fusion protein
accompanied
treatment
fabry disease
Prior art date
Application number
CONC2023/0006516A
Other languages
English (en)
Spanish (es)
Inventor
Sang Yun Kim
Jin Young Kim
Cho Rong Park
Won Ki Kim
Su Yeon Park
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CO2023006516A2 publication Critical patent/CO2023006516A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
CONC2023/0006516A 2020-11-13 2023-05-17 Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabry CO2023006516A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200152246 2020-11-13
PCT/KR2021/016629 WO2022103220A1 (ko) 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도

Publications (1)

Publication Number Publication Date
CO2023006516A2 true CO2023006516A2 (es) 2023-06-09

Family

ID=81601490

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006516A CO2023006516A2 (es) 2020-11-13 2023-05-17 Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabry

Country Status (12)

Country Link
US (1) US20230416714A1 (cg-RX-API-DMAC7.html)
EP (1) EP4245310A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549322A (cg-RX-API-DMAC7.html)
KR (1) KR20220065720A (cg-RX-API-DMAC7.html)
CN (1) CN116419759A (cg-RX-API-DMAC7.html)
AU (1) AU2021377712A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196264A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006516A2 (cg-RX-API-DMAC7.html)
IL (1) IL302857A (cg-RX-API-DMAC7.html)
MX (1) MX2023005579A (cg-RX-API-DMAC7.html)
WO (1) WO2022103220A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304536B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230134823A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
US11357834B2 (en) * 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
US20200157172A1 (en) * 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
EP3708661A4 (en) * 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE

Also Published As

Publication number Publication date
AU2021377712A9 (en) 2024-07-11
KR20220065720A (ko) 2022-05-20
AU2021377712A1 (en) 2023-06-01
MX2023005579A (es) 2023-05-29
CN116419759A (zh) 2023-07-11
US20230416714A1 (en) 2023-12-28
EP4245310A1 (en) 2023-09-20
IL302857A (en) 2023-07-01
JP2023549322A (ja) 2023-11-24
EP4245310A4 (en) 2024-10-30
WO2022103220A1 (ko) 2022-05-19
ZA202304536B (en) 2024-09-25
CA3196264A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
CO2021006092A2 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
CL2020001857A1 (es) Conjugado de enzimas terapéuticas. (divisional solicitud 201802045)
CO2021000326A2 (es) Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia genética y para eliminar o reducir las inmunoglobulinas
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
EA201592049A1 (ru) Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения
BR112022003956A2 (pt) Anticorpos anti-cd73
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
WO2021234160A3 (en) Ace2-fc fusion proteins and uses thereof
GT200900248A (es) "proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpo, que unen especificamente a cd154 y sus usos"
NZ598834A (en) Prevention, treatment and diagnosis of P. gingivalis infection
ES2184869T3 (es) Vacuna sub-unitaria contra la infeccion por flavivirus.
BRPI0912570B8 (pt) anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
MX389320B (es) Anticuerpos anti-tnfrsf25
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
MX2019006444A (es) Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
MX2020007030A (es) Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo.
CL2023003331A1 (es) Anticuerpos anti-tmprs66 y usos de los mismos.
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
BR112023008317A2 (pt) Proteínas de fusão sap fc e métodos de uso
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
BR112022017192A2 (pt) Variantes de transglutaminase
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.